195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors
| Autor: | Csiki, I., Glenn, J., Boccia, R., Chen, C., Gordon, M., Misleh, J., Powderly, J., Wainberg, Z.A., Spira, A., Klumpp, K. |
|---|---|
| Zdroj: | In Immuno-Oncology and Technology December 2022 16 Supplement 1 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|